New hope for Hard-to-Treat cancers: drug combo enters human testing
NCT ID NCT05661201
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 20 times
Summary
This early-phase study tests the safety of combining two drugs, NEROFE and doxorubicin, in people with advanced solid tumors that have a KRAS mutation and express ST2. The main goal is to find the best dose and schedule. About 24 participants will receive weekly infusions of both drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.